Skip to Main Content

Paper Details

Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.
Br J Haematol
5
2023
ABL1, ABL1 fusion, ABL1 tyrosine kinase, BCR, CML, MECOM, RNA, RUNX1, Secondary fusion proteins, cell line models, chronic myeloid leukaemia, patients, secondary fusion genes, secondary fusions, tyrosine
Cell Line, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Protein Kinase Inhibitors
Author NameAffiliation
Evan J BarnesKnight Cancer Institute, Oregon Health & Science University
Christopher A EideKnight Cancer Institute, Oregon Health & Science University
Andy KaempfKnight Cancer Institute, Oregon Health & Science University
Daniel BottomlyDepartment of Medical Informatics and Clinical Epidemiology, Knight Cancer Institute, Oregon Health & Science University
Kyle A RomineKnight Cancer Institute, Oregon Health & Science University
Beth WilmotDepartment of Medical Informatics and Clinical Epidemiology, Knight Cancer Institute, Oregon Health & Science University
Dominick SaundersKnight Cancer Institute, Oregon Health & Science University
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Knight Cancer Institute, Oregon Health & Science University
Cristina E TognonKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
  • 1 - 10

Datasets

Release 1.2